Haemonetics (HAE) Research & Development (2009 - 2026)

Haemonetics' Research & Development history runs 18 years deep, the most recent figure standing at $14.4 million for Q1 2026.

• In Q1 2026, Research & Development fell 21.08% year-over-year to $14.4 million; the TTM figure through Mar 2026 stood at $59.8 million (down 4.71% YoY), while the FY2026 annual figure was $59.8 million, down 4.71% from the prior year.
• Research & Development was $14.4 million for Q1 2026 at Haemonetics, up from $14.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $18.3 million in Q1 2025 to a low of $10.0 million in Q1 2022.
• Historically, Research & Development has averaged $13.9 million across 5 years, with a median of $14.2 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Research & Development surged 33.81% in 2022, then declined 21.08% in 2026.
• A 5-year view of Research & Development shows it stood at $12.7 million in 2022, then increased by 4.54% to $13.3 million in 2023, then rose by 19.33% to $15.8 million in 2024, then dropped by 10.37% to $14.2 million in 2025, then advanced by 1.83% to $14.4 million in 2026.
• The last three Research & Development figures came in at $14.4 million (Q1 2026), $14.2 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.